We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
Unifiram (DM-232) is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Unifiram (DM-232) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2000–2016.
Based on 5 studies
Confidence
LowBy outcome
The current evidence for Unifiram (DM-232) is insufficient to assign an evidence score, based on 5 indexed studies. A grey-market 'research chemical' sold online as a high-potency nootropic — unifiram (DM-232) is an experimental piperazine-class cognition enhancer that came out of academic work (University of Florence, ~2000) simplifying the racetam scaffold, and is the close structural cousin of sunifiram (DM-235). The CRITICAL fact is the depth of the evidence gap: there are NO human clinical trials of unifiram — not one. The ENTIRE evidence base is rodent and in-vitro pharmacology, where DM-232 reversed chemically-induced amnesia in mice at strikingly low doses (active around 0.001 mg/kg) and increased acetylcholine release and AMPA-mediated excitatory transmission in rat brain slices. It is even LESS studied than the already-grey-market sunifiram, with no human efficacy data, no human safety data, and no pharmacovigilance on the powder people actually buy. Its presumed mechanism is excitatory/ampakine-like and cholinergic, so stimulant-type harms — overstimulation, anxiety, insomnia — are plausible but entirely uncharacterised in people. Layer on the grey-market reality (unverified identity, purity and dose, often sold 'not for human consumption'), and the honest takeaway is that unifiram is an essentially unstudied-in-humans laboratory cognition enhancer, NOT an approved medicine, NOT a dietary supplement, and not a use this library can recommend. Informational, harm-reduction entry only. Representative study: PMID 10821709.
Sarcosine
Mostly mechanism / observationalAn endogenous glycine derivative that inhibits the type-1 glycine transporter (GlyT-1), enhancing NMDA-receptor co-agonism. It is studied as a prescription-style PSYCHIATRIC ADJUNCT — with genuine add-on RCTs in schizophrenia (and smaller signals in OCD and depression) — not as a casual nootropic. Evidence is real but narrow and emerging.
Tianeptine
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Unifiram (DM-232; 2-(4-fluorophenyl)sulfonyl-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-6-one) — an experimental, PRECLINICAL-ONLY grey-market 'research chemical' cognition enhancer with NO human clinical trials of any kind
A grey-market 'research chemical' sold online as a high-potency nootropic — unifiram (DM-232) is an experimental piperazine-class cognition enhancer that came out of academic work (University of Florence, ~2000) simplifying the racetam scaffold, and is the close structural cousin of sunifiram (DM-235). The CRITICAL fact is the depth of the evidence gap: there are NO human clinical trials of unifiram — not one. The ENTIRE evidence base is rodent and in-vitro pharmacology, where DM-232 reversed chemically-induced amnesia in mice at strikingly low doses (active around 0.001 mg/kg) and increased acetylcholine release and AMPA-mediated excitatory transmission in rat brain slices. It is even LESS studied than the already-grey-market sunifiram, with no human efficacy data, no human safety data, and no pharmacovigilance on the powder people actually buy. Its presumed mechanism is excitatory/ampakine-like and cholinergic, so stimulant-type harms — overstimulation, anxiety, insomnia — are plausible but entirely uncharacterised in people. Layer on the grey-market reality (unverified identity, purity and dose, often sold 'not for human consumption'), and the honest takeaway is that unifiram is an essentially unstudied-in-humans laboratory cognition enhancer, NOT an approved medicine, NOT a dietary supplement, and not a use this library can recommend. Informational, harm-reduction entry only.
Unifiram (DM-232) is a grey-market 'research chemical' cognition enhancer with NO human clinical trials of any kind — its entire evidence base is rodent and in-vitro pharmacology, almost all from the original University of Florence group. Animal work shows it reverses chemically-induced amnesia in mice at strikingly low doses (~0.001 mg/kg sc; Manetti 2000) and mechanism studies attribute this to increased acetylcholine release and AMPA-mediated excitatory transmission (Galeotti 2003; Romanelli 2006), with structure-activity mapping (Scapecchi 2004) and a discoverer's own review flagging its uncontrolled web sale despite minimal preclinical study and unknown long-term toxicity (Gualtieri 2016). None of this is human efficacy or safety evidence; unifiram is even less studied than the related sunifiram (DM-235). The presumed harm profile — CNS overstimulation, anxiety, insomnia, and theoretical AMPA-excitotoxicity/seizure-threshold concerns — is plausible from the mechanism but entirely uncharacterised in people, and the product is grey-market material of unverified identity, purity and dose. The dominant signal is therefore an ABSENCE of human data, so the score sits low.
Unifiram — development code DM-232 — is a synthetic cognition-enhancing ('nootropic') compound discovered by Gualtieri, Romanelli, Manetti, Ghelardini and colleagues at the University of Florence around 2000 as part of a programme to simplify the racetam (piracetam) structure into smaller, far more potent molecules.
Chemically it is 2-(4-fluorophenyl)sulfonyl-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-6-one — a fluorophenylsulfonyl pyrrolopyrazinone — and it is the close structural relative of sunifiram (DM-235), which differs mainly in carrying a benzoyl group in place of unifiram's fluorophenylsulfonyl group.
Both are sold online as grey-market 'research chemicals' marketed as ultra-potent memory and focus enhancers. The honest description of unifiram's evidence base is that it is ENTIRELY PRECLINICAL.
There are NO randomized controlled trials of unifiram in humans, no human pharmacokinetic studies, no approved indication anywhere, and no pharmacovigilance on the material people purchase.
Everything known comes from rodents and brain-slice experiments, almost all from the original Florence group: in the mouse passive-avoidance test DM-232 reversed amnesia induced by scopolamine and other agents and was active at remarkably low doses (around 0.001 mg/kg subcutaneously), making it roughly four orders of magnitude more potent than piracetam (Manetti 2000; Romanelli 2006).
Mechanistically it does not show appreciable binding affinity for the major classical receptors; instead it increases acetylcholine release from rat cerebral cortex and enhances AMPA-mediated excitatory synaptic transmission, and its anti-amnesic effect is blocked by the AMPA-receptor antagonist NBQX — pointing to an ampakine-like, glutamatergic/cholinergic mechanism (Galeotti 2003; Romanelli 2006).
Structure-activity work mapped how the scaffold can be tuned (Scapecchi 2004; Martini 2008), but none of this is human evidence.
It is essential not to over-read these findings: 'active at 0.001 mg/kg in a mouse memory test' is a statement about rodent pharmacology, not a demonstration that unifiram improves cognition, or is safe, in a person.
Crucially, unifiram is even LESS studied than sunifiram — there are fewer papers, and no human data for either — so any 'benefit' a buyer expects is an extrapolation from animal models of a compound made and sold outside any quality system.
The presumed harm profile follows from the mechanism rather than from measurement: an excitatory, ampakine-like, cholinergic cognition enhancer would plausibly produce CNS overstimulation, anxiety, headache and insomnia, and excessive glutamatergic/AMPA activity carries theoretical excitotoxicity and seizure-threshold concerns — but none of this has been characterised in humans, so doses, tolerability and serious-harm risk are simply unknown.
On top sits the grey-market reality: a powder of unverified identity, purity and dose, frequently labelled 'not for human consumption', taken with no medical supervision, no monitoring, and no interaction data.
A 2015 review by Gualtieri — one of the molecule's own discoverers — documented exactly this trajectory, expressing concern that compounds disclosed academically with only a few preclinical studies and unknown long-term toxicity were being sold across dozens of websites as cognition enhancers for healthy people (Gualtieri 2016).
The evidence score sits low and the level is 'Emerging' precisely because the dominant signal is an ABSENCE of any human data whatsoever, against a plausible-but-unmeasured stimulant/excitotoxic harm profile and grey-market quality risk.
This is an informational, harm-reduction entry: the responsible conclusion is that unifiram is an experimental, preclinical-only cognition enhancer sold as a nootropic, not a supported intervention, and there is no human use this library endorses.
In rat hippocampal slices, unifiram (DM-232) increases AMPA-mediated excitatory synaptic transmission, and its anti-amnesic effect in mice is abolished by the AMPA-receptor antagonist NBQX — pointing to an ampakine-like potentiation of glutamatergic neurotransmission as a core mechanism (Galeotti 2003). This is characterised only in rodents and brain slices; its human pharmacology is unknown, and excess AMPA/glutamatergic drive carries theoretical excitotoxicity and seizure-threshold concerns.
Unifiram increases the release of acetylcholine from rat cerebral cortex and prevents amnesia induced by interfering with several neurotransmitter systems, without showing appreciable binding affinity for the major classical receptors or channels (Romanelli 2006). This pro-cholinergic, pro-excitatory profile is consistent with cognition-enhancing activity in animal models, but is inferred entirely from rodent/in-vitro data.
Because unifiram is sold as an unregulated 'research chemical', the actual substance, its purity, its real dose and how a human body absorbs and metabolises it are not assured or characterised. There are no human pharmacokinetic data at all — so what a buyer ingests, how potent it is, and how the body handles it are unknown, a point flagged by the compound's own discoverer when describing its uncontrolled web sale (Gualtieri 2016).
How Unifiram (DM-232) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
There is no established or legitimate human dose. Unifiram (DM-232) is a preclinical-only grey-market 'research chemical' with NO human clinical trials, no human pharmacokinetic data, no approval and no pharmacovigilance — this library does NOT provide a dosing protocol. Vendors and forums quote figures in the single-to-low-tens of milligrams orally, but these are pure extrapolation, not validated for a product of unknown identity and purity taken without supervision or monitoring. The only quantitative figure in the literature is an animal one — DM-232 was active at about 0.001 mg/kg subcutaneously in the mouse passive-avoidance test (Manetti 2000) — which is a rodent research dose by a non-oral route, NOT a human recommendation and not convertible into one.
Can be taken without food
| Form | Type |
|---|---|
| 💊No human form is endorsed — unifiram is a preclinical-only 'research chemical' with no approved or supplement form | Recommended |
There is no over-the-counter, supplement or prescription form of unifiram. Grey-market powder/capsules are of unverified identity and purity and are frequently sold 'not for human consumption', and are easily confused with the related compound sunifiram (DM-235).
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: No human timing is endorsed. Unifiram is a preclinical-only grey-market cognition enhancer with no human trials and a presumed excitatory/stimulant harm profile (overstimulation, anxiety, insomnia, theoretical excitotoxicity). Morning-only framing is harm-reduction to limit insomnia if exposure occurs; this library does not schedule its use.
Dose-response data unavailable. The current published research for Unifiram (DM-232) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
There are no human clinical trials of unifiram of any kind — no demonstrated cognitive, memory or focus benefit in people, and no human safety or pharmacokinetic data. Every result for unifiram comes from rodent memory tests or brain-slice experiments. Any 'benefit' claimed for unifiram is extrapolated from animal models, not measured in humans, and it is even less studied than the related sunifiram.
In the mouse passive-avoidance test, unifiram (DM-232) reversed chemically-induced amnesia at strikingly low doses (~0.001 mg/kg subcutaneously), making it roughly four orders of magnitude more potent than piracetam (Manetti 2000; Romanelli 2006). This is a rodent pharmacology result, NOT a human cognition result — there is no human trial of unifiram for memory, so any procognitive benefit in people is assumed, not shown, and comes bundled with the presumed stimulant harms below.
Because unifiram enhances excitatory/cholinergic neurotransmission in animals, users buy it expecting sharper focus and attention. No human study has tested unifiram for focus or attention, so any such benefit is an inference from its rodent mechanism, not a trial result, and may not transfer to a person at unknown doses of a grey-market powder.
As an excitatory, ampakine-like, cholinergic cognition enhancer, unifiram is expected to carry stimulant-type effects — overstimulation, anxiety, restlessness, headache and difficulty sleeping. None of this is characterised in humans: there is no dose-finding and no monitoring, so the threshold and severity of overstimulation are unknown for the material people actually take.
Unifiram's core mechanism is potentiation of AMPA-mediated glutamatergic excitation. Excess glutamatergic/AMPA drive carries theoretical risks of excitotoxicity and a lowered seizure threshold. This hazard is mechanistic and unquantified in humans — there is no human safety data to bound it — and is compounded by unknown grey-market doses.
Unifiram is sold as an unregulated 'research chemical' of unverified identity, purity and dose, frequently labelled 'not for human consumption' — a problem flagged by its own discoverer (Gualtieri 2016). With no human pharmacokinetic data, a buyer cannot know what the powder is, how potent it is, or how their body will handle it, with no medical supervision or monitoring of any kind.
Avoid — unifiram is unstudied in humans, of unverified identity and dose, and carries a presumed excitatory/stimulant harm profile (overstimulation, anxiety, insomnia, theoretical excitotoxicity). There is no human evidence of benefit, and it is even less studied than the related sunifiram.
Avoid — unifiram potentiates AMPA-mediated glutamatergic excitation, a theoretical seizure/excitotoxicity hazard taken with no monitoring.
Avoid — a CNS-excitatory cognition enhancer of unknown human potency is taken with no dose-finding or monitoring.
Avoid entirely — there is no human or developmental safety data of any kind.
Avoid — additive overstimulation and excitotoxicity risk with no interaction data for unifiram.
Combining unifiram with caffeine, other ampakines/racetams, ADHD stimulants or cholinergic agents could compound excitatory and pro-cholinergic effects (overstimulation, anxiety, insomnia). The additive effect is entirely uncharacterised in humans and is unpredictable in a product of unknown potency.
Unifiram potentiates AMPA-mediated excitation; stacking it with other glutamatergic or AMPA-active substances could theoretically increase excitotoxicity and seizure-threshold concerns. There is no human data to bound this combined risk.
Tip: Presumed of an excitatory ampakine-like/cholinergic cognition enhancer; there is no human dose-finding to bound it. The only harm-reduction note is that no validated human dose exists — stop use if overstimulation, anxiety or agitation occur.
Tip: Expected of a pro-excitatory cognition enhancer, especially later in the day. There is no validated dosing to limit this; if exposure occurs, evening use is worse than morning.
Tip: Commonly reported with excitatory nootropics by anecdote; uncharacterised for unifiram specifically. With an unstudied compound of uncertain potency there is no dose-finding to bound it — discontinue if it occurs.
Tip: A mechanistic, unquantified risk from AMPA/glutamatergic potentiation, with no human safety data. Anyone with a seizure history or on seizure-threshold-lowering drugs should avoid entirely; any seizure, severe confusion or loss of consciousness after use is a medical emergency.
The commonly studied dose of Unifiram (DM-232) is There is no established or legitimate human dose. Unifiram (DM-232) is a preclinical-only grey-market 'research chemical' with NO human clinical trials, no human pharmacokinetic data, no approval and no pharmacovigilance — this library does NOT provide a dosing protocol. Vendors and forums quote figures in the single-to-low-tens of milligrams orally, but these are pure extrapolation, not validated for a product of unknown identity and purity taken without supervision or monitoring. The only quantitative figure in the literature is an animal one — DM-232 was active at about 0.001 mg/kg subcutaneously in the mouse passive-avoidance test (Manetti 2000) — which is a rodent research dose by a non-oral route, NOT a human recommendation and not convertible into one.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Unifiram (DM-232) is in the morning. It can be taken on an empty stomach. An excitatory, cholinergic cognition enhancer would plausibly disrupt sleep if taken late in the day, so morning framing is harm-reduction only.
Unifiram (DM-232) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are CNS overstimulation / anxiety / restlessness, insomnia / disrupted sleep, headache. Use caution if any of these apply to you: Any human use — unifiram (DM-232) is a preclinical-only grey-market 'research chemical' with NO human trials, no approval, and product of unverified identity, purity and dose; it is NOT a dietary supplement and NOT an approved medicine; Anyone seeking it for memory, focus or 'nootropic' enhancement — there is no human evidence of benefit for unifiram and a presumed excitatory/stimulant harm profile; Anyone with a seizure disorder or lowered seizure threshold — unifiram potentiates AMPA-mediated glutamatergic excitation, which carries theoretical seizure/excitotoxicity risk.
An atypical antidepressant — brand Stablon/Coaxil/Tatinol — approved and prescribed for major depression (and anxious depression) in parts of Europe, Asia and Latin America, where randomized trials show efficacy comparable to SSRIs and tricyclics, often with better tolerability at the therapeutic dose (12.5 mg three times daily). Mechanistically it is unusual: it modulates the stress system and enhances glutamatergic/hippocampal plasticity, and — the critical fact for harm reduction — it is a FULL MU-OPIOID RECEPTOR AGONIST. That opioid action explains both its antidepressant effect AND its abuse potential. In the United States it is NOT FDA-approved; the FDA has warned about it, and it is sold illicitly as an unapproved 'nootropic'/'supplement' ('Tianaa', 'Za Za', 'Pegasus') nicknamed 'gas station heroin'. The dominant recent US literature is not efficacy but ABUSE, DEPENDENCE, opioid-like WITHDRAWAL, overdose/toxicity (usually at supratherapeutic doses far above the clinical dose), and rising poison-center exposures. The honest framing: a genuine antidepressant abroad with proven short-term efficacy at the prescribed dose, but a mu-opioid agonist carrying real dependence/abuse/withdrawal/overdose risk and no US approval. Informational, harm-reduction entry only — not a recommendation, and not a substitute for clinician-supervised treatment.
Because the presumed mechanism increases excitatory neurotransmission, co-use with agents that lower the seizure threshold (e.g. certain antidepressants, tramadol, bupropion) is a theoretical and unmonitored risk; no interaction data exist for unifiram.
Stacking a CNS-excitatory cognition enhancer of unknown human pharmacology with antidepressants, antipsychotics or sedatives risks unpredictable additive or opposing CNS effects; unifiram has no human interaction data, so any combination is uncharacterised and unsafe to assume benign.
Tip: A 'research chemical' of unverified composition can contain the wrong compound, contaminants, or a wildly different dose. There is no way to bound this without a quality system; the only mitigation is not to take an unidentified powder.